A reallocation pretending to be an investment
The headline numbers sound decisive. The government’s science funding overhaul shifts $111 million over three years into advanced technology, an 88% increase for that category. The source of the money is less impressive: $56 million stripped from primary industries and bioeconomy, $18 million from environmental sustainability, and $37 million from human and social health.
No new funding enters the system. This is a zero-sum shuffle inside a science budget that is already chronically undersized. New Zealand’s R&D spending sits at 1.54% of GDP. The OECD average is 2.7%. Israel, the innovation economy this government admires, invests 5.9%. An NZIER analysis found that matching the OECD average in 2020 would have required $8.4 billion in R&D, nearly double the actual $4.5 billion spent that year.
Dr James Hutchinson, CEO of KiwiNet, the body that translates public research into commercial outcomes, warned explicitly that “game-changing innovation does not come from translation alone” and that treating this as a “zero-sum exercise at current funding levels” is the wrong approach.
The Marsden Fund gets gutted by design
The Marsden Fund is New Zealand’s only dedicated vehicle for curiosity-driven discovery research. In its most recent round, it funded 113 projects worth $75.82 million from a pool with a 10% success rate. The government has now mandated that 50% of Marsden grants must demonstrate economic benefit, with social sciences and humanities removed entirely.
Professor Nicola Gaston of the University of Auckland and co-director of the MacDiarmid Institute for Advanced Materials and Nanotechnology identified the logical problem: “If we knew the outcomes, it wouldn’t be research, and any knowledge produced would not be new.” You cannot specify commercial returns for work whose entire value lies in producing unexpected results.
Cather Simpson, a University of Auckland physicist and founder of three deep-tech startups, put it more bluntly: “We’ve been eating our seed corn with our overemphasis on short-term economic impact for a wee while; this change means we’ll be scoffing it down.”
The Irish model without the Irish money
Prime Minister Christopher Luxon has explicitly cited the Irish model as the template. Pick clusters, back winners, drive commercialisation. The problem is that the man whose model this is already said it will not work here. Former Irish PM Leo Varadkar warned that “a kiwi can never be a tiger,” a direct caution that the Irish approach requires investment levels New Zealand is not committing to.
Copying the strategy while spending half the OECD average on R&D is not ambition. It is a category error.
Paying to rebuild what was just demolished
The government’s $70 million AI research platform is being presented as forward-looking investment. But Callaghan Innovation had already built AI capability through an activator programme. That institutional knowledge was destroyed through redundancies, with the first year’s budget for the new platform roughly equalling the redundancy payouts. New Zealand is spending money to rebuild capacity it just paid to demolish.
The innovation base is already narrowing
Stats NZ’s 2024 R&D survey shows total business R&D hit $4.0 billion, up 9% from 2023. But the number of entities performing R&D fell 2% to 2,337, while average spend per entity rose 24%. R&D is concentrating among fewer, larger players. Reforms that prioritise near-term commercial outcomes will accelerate this trend, favouring incumbents with defined roadmaps over the smaller exploratory firms where disruptive ideas typically originate.
For businesses that want to commercialise genuinely novel IP, the upstream discovery layer must exist. Cut it, and New Zealand becomes a technology importer, buying innovations developed elsewhere at a premium and without strategic proximity to their development.
What the fiscal reality locks in
Dame Jane Harding, president of Royal Society Te Apārangi, warned that future funding decisions could be influenced by factors beyond research excellence under the new consolidated governance structure. Professor Richard Easther captured the asymmetric risk: “Demanding fruit from trees you refuse to water is not a growth strategy. It is liquidation by another name.”
With Treasury forecasting Crown net worth falling 10% to $172 billion by 2029, the standard promise of growing the funding envelope later looks hollow. This reallocation is not a bridge. It is the permanent architecture of a science system that has chosen to consume its future to fund its present.
Sources
- Newsroom: Science funding shakeup to shift millions from farms to advanced tech (2026-04-07)
- B2B News: NZ science reforms risk hollowing research pipeline for $111m tech bet
- Newsroom: NZ’s science reforms all shell, no substance (2026-04-12)
- NZ Herald: Funding research for economic return sounds good – but that’s not how science really works
- RNZ: Funding research for economic return sounds good – but that’s not how science really works
- Newsroom: A kiwi can never be a tiger, warns Ireland’s former PM (2025-08-08)
- Newsroom: Future of discovery research uncertain after science funding overhaul (2025-10-16)
- Stats NZ: Research and development survey 2024 (2024)
- Newsroom: Mending the public-private rift to do the science that NZ needs (2024-02-22)